<
https://theconversation.com/first-mrna-flu-shot-approved-by-fda-bodes-well-for-improving-drugs-of-the-future-though-a-few-hurdles-remain-before-mrna-can-move-beyond-vaccines-289277>
"Vaccines have been reliably and affordably protecting people from diseases
worldwide for centuries. Until the COVID-19 pandemic, however, vaccine
development was still a long and idiosyncratic process. Traditionally,
researchers had to tailor manufacturing processes and facilities for each
vaccine candidate, and the scientific knowledge gained from one vaccine was
often not directly transferable to another.
But the COVID-19 mRNA vaccines brought a new approach to vaccine development.
And on Aug. 5, 2026, the U.S. Food and Drug Administration approved another
mRNA vaccine – a seasonal flu vaccine for adults age 50 or older – that offers
more protection against influenza compared to standard vaccines. These advances
demonstrate the momentum of mRNA technology, and they have far-reaching
implications for how researchers make drugs to treat many other diseases.
Although there are many possibilities for what researchers can use mRNA to
treat, some important limitations remain. My work as a biochemist and my lab at
UMass Chan Medical School focus on developing better ways to use mRNA as a
drug. Better understanding how mRNA-based drugs interact with the immune system
and how they are degraded in human cells can help lead to safe, durable and
effective treatments for a wide range of diseases."
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
